Related Experiment Video
Updated: Jul 20, 2025

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Myocardial Fibrosis and Cardiomyopathy Risk: A Genetic Link in the MESA
Mahsima Shabani1, Min Wang2, Gregory D Jenkins3
1Division of Cardiology, Department of Medicine (M.S., J.A.C.L.), Johns Hopkins University School of Medicine, Baltimore, MD.
Insights
Genetic variants in SMARCB1 are linked to increased myocardial fibrosis, a key factor in cardiomyopathies. This finding may reveal a new pathway connecting genetic risk to heart disease development.
Area of Science:
- Cardiovascular Genetics
- Molecular Cardiology
- Genetic Epidemiology
Background:
- Common genetic variants influence hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) risk.
- These variants are also linked to left ventricular (LV) traits.
- The association between these genetic variants and myocardial fibrosis, a key mediator of cardiomyopathy, remains unclear.
Purpose of the Study:
- To investigate the association between common genetic variants and myocardial fibrosis.
- To explore the role of these variants in extracellular volume, a marker of myocardial fibrosis.
- To examine the functional impact of identified variants on gene expression and fibrosis-related pathways.
Main Methods:
- Utilized data from the Multi-Ethnic Study of Atherosclerosis (N=1255) with cardiac MRI and genotyping.
- Regressed log extracellular volume on 50 candidate single nucleotide polymorphisms (SNPs) associated with cardiomyopathy and LV traits.
- Performed fixed-effect meta-analyses for ancestry-specific results and conducted gene knockdown experiments in human cardiac fibroblasts.
Main Results:
- The SMARCB1 rs2186370 variant, associated with HCM and DCM risk, showed a significant association with increased extracellular volume (P=0.0002).
- The SMARCB1 rs2070458 locus, linked to LV wall thickness and mass, was also significantly associated with increased extracellular volume (P=0.0002).
- SMARCB1 variants are expression quantitative loci in human LV tissue, decreasing SMARCB1 expression and leading to increased TGF-β1-mediated fibrosis markers in vitro.
Conclusions:
- Common genetic variation in SMARCB1 is associated with increased myocardial fibrosis, assessed by cardiac MRI.
- These findings suggest a potential pathophysiological link between SMARCB1 variants, myocardial fibrosis, and cardiomyopathy risk.
- Further research is needed to confirm if these genetic associations translate to a direct pathophysiological link in cardiomyopathy development.
Background:
Common genetic variants are associated with risk for hypertrophic cardiomyopathy and dilated cardiomyopathy and with left ventricular (LV) traits. Whether these variants are associated with myocardial fibrosis, an important pathophysiological mediator of cardiomyopathy, is unknown.
Methods:
Multi-Ethnic Study of Atherosclerosis participants with T1-mapping cardiac magnetic resonance imaging in-whom extracellular volume was assessed, and genotyping information was available were included (N=1255). Log extracellular volume (%) was regressed on 50 candidate single nucleotide polymorphisms (previously identified to be associated with hypertrophic cardiomyopathy, dilated cardiomyopathy, and LV traits) adjusting for age, sex, diabetes, blood pressure, and principal components of ancestry. Ancestry-specific results were pooled by fixed-effect meta-analyses. Gene knockdown experiments were performed in human cardiac fibroblasts.
Results:
The SMARCB1 rs2186370 intronic variant (minor allele frequency: 0.18 in White and 0.50 in Black participants), previously identified as a risk variant for dilated cardiomyopathy and hypertrophic cardiomyopathy, was significantly associated with increased extracellular volume (P=0.0002) after adjusting for confounding clinical variables. The SMARCB1 rs2070458 locus previously associated with increased LV wall thickness and mass was similarly significantly associated with increased extracellular volume (P=0.0002). The direction of effect was similar in all 4 ancestry groups, but the effect was strongest in Black participants. The variants are strong expression quantitative loci in human LV tissue and associated with genotype-dependent decreased expression of SMARCB1 (P=7.3×10-22). SMARCB1 knockdown in human cardiac fibroblasts resulted in increased TGF (transforming growth factor)-β1-mediated α-smooth muscle actin and collagen expression.
Conclusions:
Common genetic variation in SMARCB1 previously associated with risk for cardiomyopathies and increased LV wall thickness is associated with increased cardiac magnetic resonance imaging-based myocardial fibrosis and increased TGF-β1 mediated myocardial fibrosis in vitro. Whether these findings suggest a pathophysiologic link between myocardial fibrosis and cardiomyopathy risk remains to be proven.
More Related Videos
10:21Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
Published on: June 14, 2016
09:16Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients
Published on: February 28, 2018
Related Concept Videos
Myocarditis I: Introduction
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy V: Interprofessional Care